Nicholas Dyson is Professor of Medicine at Harvard Medical School, the James and Shirley Curvey MGH Research Scholar and Scientific Director of the Massachusetts General Hospital Cancer Center.[1]
Nicholas Dyson | |
|---|---|
| Known for | E2F and pRB |
| Scientific career | |
| Institutions | Massachusetts General Hospital Cancer Center |
| Academic advisors | Ed Harlow |
| Doctoral students | Simon Boulton Adam Brook |
| Website | www |
Research
editThe Dyson Lab studies the retinoblastoma protein.
Working as a post-doctoral fellow in the laboratory of Dr. Ed Harlow, Dyson demonstrated that the retinoblastoma protein can form complexes in vitro with the E7 oncoprotein of Human papilloma virus type-16.[2] This result implicated pRB binding to E7 as a step in human papilloma virus-associated carcinogenesis.
More recently, Dyson's group has shown that the transcription factor E2F1 is a potent and specific inhibitor of beta-catenin/T-cell factor (TCF)-dependent transcription, and that this function contributes to E2F1-induced apoptosis.[3]
As of 2015, Professor Dyson has 140 publications in leading peer-reviewed journals.
References
edit- ^ "Dyson Lab - Massachusetts General Hospital, Boston, MA". www.massgeneral.org. Massachusetts General Hospital.
- ^ Dyson, N; Howley, PM; Munger, K; Harlow, E (1989). "The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product". Science. 243 (4893): 934–7. Bibcode:1989Sci...243..934D. doi:10.1126/science.2537532. PMID 2537532.
- ^ Morris, E; Ji, J; Yang, F; Di Stefano, L; Herr, A; Moon, N; Kwon, E; Haigis, K; Naar, A; Dyson, N (2008). "E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8". Nature. 455 (7212): 552–6. Bibcode:2008Natur.455..552M. doi:10.1038/nature07310. PMC 3148807. PMID 18794899.